ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 6, 2021

8:30AM-10:30AM: Abstract Number: 0004

Unappreciated Systemic Metabolic Functions of the Canonical B Cell Cytokines, BAFF and APRIL: Regulation of Lipolysis and Non-shivering Thermogenesis and Protection from Obesogenic Diet Induced Weight Gain

B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)

8:30AM-10:30AM: Abstract Number: 0136

Underutilization of Mental Health Services in a Busy Tertiary Care Rheumatology Facility

Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)

8:30AM-10:30AM: Abstract Number: 0021

Unique Alterations in Circulating T Peripheral Helper Cells Are Found in Different Ethnic Groups of ACPA+ Individuals Both At-risk for and with Classified RA

RA – Etiology & Pathogenesis Poster (0011–0045)

8:30AM-10:30AM: Abstract Number: 0212

Unsupervised Clustering of Histology and Ultrasound Scores Identifies Osteoarthritis Subtypes

Osteoarthritis – Clinical Poster I (0210–0224)

8:30AM-10:30AM: Abstract Number: 0281

Unsupervised Machine Learning of Expanded Autoantibodies, Cytokines, and Chemokines Improves the Identification of Interstitial Lung Disease in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)

8:30AM-10:30AM: Abstract Number: 0211

Unsupervised Machine-learning Algorithms for the Identification of Clinical Phenotypes in the Osteoarthritis Initiative Database

Osteoarthritis – Clinical Poster I (0210–0224)

8:30AM-10:30AM: Abstract Number: 0340

Urinary L-selectin Predicts Disease Activity and Histological Changes in Lupus Nephritis

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

8:30AM-10:30AM: Abstract Number: 0331

Urinary MicroRNAs as Systemic Lupus Erythematosus Biomarkers and Its Potential for Accurate Assessment of Disease Severity

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

8:30AM-10:30AM: Abstract Number: 0423

Urine and Plasma Complement Ba Levels During Flares of Nephritis in Patients with ANCA-Associated Vasculitis

Vasculitis – ANCA-Associated Poster (0414–0436)

8:30AM-10:30AM: Abstract Number: 0433

Use of 2-Mercaptoethane Sodium Sulfonate Prophylaxis in Cyclophosphamide-Treated Patients with ANCA-Associated Vasculitis: Results of an Electronic Survey

Vasculitis – ANCA-Associated Poster (0414–0436)

8:30AM-10:30AM: Abstract Number: 0389

Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States

Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)

8:30AM-10:30AM: Abstract Number: 0151

Usefulness of Ultrasound and (FDG) PET/CT to Detect Cranial and Extracranial Artery Involvement in Patients with Suspected Large Vessel Vasculitis

Imaging of Rheumatic Diseases Poster (0149–0182)

8:30AM-10:30AM: Abstract Number: 0210

Using Machine Learning to Predict Medial Knee Cartilage Worsening over 2 Years Using Gait and Physical Activity: The MOST Study

Osteoarthritis – Clinical Poster I (0210–0224)

8:30AM-10:30AM: Abstract Number: 0415

Utility of the 22-Item Sinonasal Outcome Test Patient-Reported Outcome Instrument in ANCA-Associated Vasculitis

Vasculitis – ANCA-Associated Poster (0414–0436)

8:30AM-10:30AM: Abstract Number: 0355

Utilization of a Clinical Data Research Network to Assess Systemic Lupus International Collaborating Clinics Classification Criteria Attributes in Patients with Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].